Research programme: bacteriophage therapeutics - BioPhage Therapeutics/Intralytix

Drug Profile

Research programme: bacteriophage therapeutics - BioPhage Therapeutics/Intralytix

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioPhage Therapeutics; Intralytix
  • Class Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Wound infections

Most Recent Events

  • 04 Apr 2017 Intralytix and BioPhage Therapeutics collaborate to develop topical phage-based therapeutics for Wound infections
  • 04 Apr 2017 Early research in Wound infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top